The Ubiquitin Carboxyl Terminal Hydrolase 1 pipeline drugs market research report outlays comprehensive information on the Ubiquitin Carboxyl Terminal Hydrolase 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Ubiquitin Carboxyl Terminal Hydrolase 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Gastrointestinal which include the indications Ovarian Cancer, Unspecified Cancer, and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). It also reviews key players involved in Ubiquitin Carboxyl Terminal Hydrolase 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Ubiquitin Carboxyl Terminal Hydrolase 1 pipeline targets constitutes close to seven molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 2, 3, and 2 respectively.
Ubiquitin Carboxyl Terminal Hydrolase 1 overview
Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) is a cysteine protease that plays a critical role in the ubiquitin-proteasome system (UPS). The UPS is responsible for degrading proteins that are no longer needed or are damaged. UCH-L1 is responsible for removing the ubiquitin tag from proteins that have been marked for degradation. This is an important step in the UPS, as it allows the proteasome to break down the proteins and recycle the amino acids.
For a complete picture of Ubiquitin Carboxyl Terminal Hydrolase 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
